MRK

Merck & Co., Inc.
$122.41
+6.53 (+5.64%)
Mkt Cap 302.33B
Volume 12,239,197
52W Range 75.4-125.14
Sector Healthcare
Beta 0.20
EPS (TTM) 3.56
P/E Ratio 34.38
Revenue (TTM) 65.59B
Rev Growth (5Y) +9.4%
EPS Growth (5Y) +21.2%
AlphaVal · Fair Value
$124.77
Fair Value · Mild
1.9% below fair value
AlphaQuality · Grade
B+
Stable Earnings Power
78.8 / 100 composite

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 64.93B 64.17B 60.12B 59.28B 48.70B 41.52B 39.12B 42.29B 40.12B 39.81B 39.50B 42.24B
Net Income 18.25B 17.12B 365.00M 14.52B 13.05B 7.07B 9.84B 6.22B 2.39B 3.92B 4.44B 11.92B
EPS 7.30 6.76 0.14 5.73 5.16 2.79 3.84 2.40 0.95 2.07 1.60 4.20
Free Cash Flow 12.36B 18.10B 9.14B 14.71B 9.66B 5.82B 9.97B 8.31B 4.56B 8.76B N/A N/A
FCF / Share 4.94 7.15 3.51 5.81 3.82 2.30 3.89 3.20 1.69 3.19 N/A N/A
Operating CF 16.47B 21.47B 13.01B 19.09B 14.11B 10.25B 13.44B 10.92B 6.45B 10.38B N/A N/A
Total Assets 136.87B 117.11B 106.67B 109.16B 105.69B 91.59B 84.40B 82.64B 87.87B 95.38B N/A N/A
Total Debt 50.53B 38.27B 36.27B 31.98B 34.63B 33.42B 27.35B 25.11B 24.41B 24.84B N/A N/A
Cash & Equiv 14.56B 13.24B 6.84B 12.69B 8.10B 8.05B 9.68B 7.96B 6.09B 6.51B N/A N/A
Book Value 52.61B 46.31B 37.58B 45.99B 38.18B 25.32B 25.91B 26.70B 34.34B 40.09B N/A N/A
Return on Equity 0.35 0.37 0.01 0.32 0.34 0.28 0.38 0.23 0.07 0.10 N/A N/A
MRK News
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities
May 22, 2026 12:41 PM · fool.com
Merck stock jumps as Keytruda combo trials boost cancer pipeline
May 22, 2026 10:31 AM · invezz.com
Will Weak Gardasil Sales Continue to Ail MRK's Vaccines Sales in 2026?
May 22, 2026 08:15 AM · zacks.com
Pharma Stock Pops On European Seal of Approval
May 22, 2026 06:51 AM · schaeffersresearch.com
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.
May 22, 2026 06:23 AM · barrons.com
Merck Stock Zooms Closer To A Breakout On 'A New Chapter' In Cancer
May 22, 2026 05:07 AM · investors.com
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
May 22, 2026 03:55 AM · businesswire.com
Kelun, Merck's lung cancer combo improves survival in late-stage China trial
May 21, 2026 01:06 PM · reuters.com
Moderna, Merck cancer combo cuts melanoma spread risk at five years
May 21, 2026 01:03 PM · reuters.com
Eli Lilly vs. Merck: Which Pharma Stock Looks Stronger Now?
May 21, 2026 07:16 AM · zacks.com